Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2009;329:129–162. doi: 10.1007/978-3-540-70523-9_7

Reverse Genetics of Measles Virus and Resulting Multivalent Recombinant Vaccines: Applications of Recombinant Measles Viruses

M A Billeter 10,✉, H Y Naim 11, S A Udem 12
Editors: Diane E Griffin1, Michael B A Oldstone6
PMCID: PMC7120638  PMID: 19198565

Abstract

An overview is given on the development of technologies to allow reverse genetics of RNA viruses, i.e., the rescue of viruses from cDNA, with emphasis on nonsegmented negative-strand RNA viruses ( Mononegavirales ), as exemplified for measles virus (MV). Primarily, these technologies allowed site-directed mutagenesis, enabling important insights into a variety of aspects of the biology of these viruses. Concomitantly, foreign coding sequences were inserted to (a) allow localization of virus replication in vivo through marker gene expression, (b) develop candidate multivalent vaccines against measles and other pathogens, and (c) create candidate oncolytic viruses. The vector use of these viruses was experimentally encouraged by the pronounced genetic stability of the recombinants unexpected for RNA viruses, and by the high load of insertable genetic material, in excess of 6 kb. The known assets, such as the small genome size of the vector in comparison to DNA viruses proposed as vectors, the extensive clinical experience of attenuated MV as vaccine with a proven record of high safety and efficacy, and the low production cost per vaccination dose are thus favorably complemented.

Keywords: Newcastle Disease Virus, Measle Virus, Chloramphenicol Acetyl Transferase, Helper Virus, Venezuelan Equine Encephalitis Virus

Contributor Information

Diane E. Griffin, Email: dgriffin@mail.jhmi.edu, Email: dgriffin@jhsph.edu

Michael B. A. Oldstone, Email: mbaobo@scripps.edu

M. A. Billeter, Email: billeter@access.unizh.ch

References

  1. Andino R, Silvera D, Suggett SD, Achacoso PL, Miller CJ, Baltimore D, Feinberg MB. Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science. 1994;265:1448–1451. doi: 10.1126/science.8073288. [DOI] [PubMed] [Google Scholar]
  2. Arroyo J, Miller C, Catalan J, Myers GA, Ratterree MS, Trent DW, Monath TP. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immuno- genicity, and efficacy. J Virol. 2004;78:12497–12507. doi: 10.1128/JVI.78.22.12497-12507.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Atkins GJ, Sheahan BJ, Liljestrom P. Manipulation of the Semliki Forest virus genome and its potential for vaccine construction. Mol Biotechnol. 1996;5:33–38. doi: 10.1007/BF02762410. [DOI] [PubMed] [Google Scholar]
  4. Bailly JE, McAuliffe JM, Durbin AP, Elkins WR, Collins PL, Murphy BR. A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates. J Virol. 2000;74:3188–3195. doi: 10.1128/jvi.74.7.3188-3195.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baron MD, Barrett T. Rescue of rinderpest virus from cloned cDNA. J Virol. 1997;71:1265–1271. doi: 10.1128/jvi.71.2.1265-1271.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bass BL, Weintraub H, Cattaneo R, Billeter MA. Biased hypermutation of viral RNA genomes could be due to unwinding/modification of double-stranded RNA. Cell. 1989;56:331. doi: 10.1016/0092-8674(89)90234-1. [DOI] [PubMed] [Google Scholar]
  7. Bennett J V, de Fernandez Castro J, Valdespino-Gomez JL, Mde Garcia-Garcia L, Islas-Romero R, Echaniz-Aviles G, Jimenez-Corona A, Sepulveda-Amor J. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull World Health Organ. 2002;80:806–812. [PMC free article] [PubMed] [Google Scholar]
  8. Bergman I, Griffin JA, Gao Y, Whitaker-Dowling P. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. Int J Cancer. 2007;121:425–430. doi: 10.1002/ijc.22680. [DOI] [PubMed] [Google Scholar]
  9. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet. 1971;2:105–106. doi: 10.1016/s0140-6736(71)92086-1. [DOI] [PubMed] [Google Scholar]
  10. Brandler S, Tangy F. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Comp Immunol Microbiol Infect Dis. 2007;31:271–291. doi: 10.1016/j.cimid.2007.07.012. [DOI] [PubMed] [Google Scholar]
  11. Brandler S, Brown N, Ermak TH, Mitchell F, Parsons M, Zhang Z, Lang J, Monath TP, Guirakhoo F. Replication of chimeric yellow fever virus-dengue serotype 1–4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg. 2005;72:74–81. [PubMed] [Google Scholar]
  12. Brandler S, Lucas-Hourani M, Moris A, Frenkiel MP, Combredet C, Fevrier M, Bedouelle H, Schwartz O, Despres P, Tangy F. Pediatric measles vaccine expressing a Dengue antigen induces durable serotype-specific neutralizing antibodies to Dengue virus. PLoS Negl Trop Dis. 2007;1:e96. doi: 10.1371/journal.pntd.0000096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Brandsma JL, Shylankevich M, Su Y, Roberts A, Rose JK, Zelterman D, Buonocore L. Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol. 2007;81:5749–5758. doi: 10.1128/JVI.02835-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Brave A, Ljungberg K, Wahren B, Liu MA. Vaccine delivery methods using viral vectors. Mol Pharm. 2007;4:18–32. doi: 10.1021/mp060098+. [DOI] [PubMed] [Google Scholar]
  15. Buchholz UJ, Finke S, Conzelmann KK. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol. 1999;73:251–259. doi: 10.1128/jvi.73.1.251-259.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Calain P, Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol. 1993;67:4822–4830. doi: 10.1128/jvi.67.8.4822-4830.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Cattaneo R, Billeter MA. Mutations and A/I hypermutations in measles virus persistent infections. Curr Top Microbiol Immunol. 1992;176:63–74. doi: 10.1007/978-3-642-77011-1_5. [DOI] [PubMed] [Google Scholar]
  18. Cattaneo R, Schmid A, Eschle D, Baczko K, ter Meulen V, Billeter MA. Biased hypermuta- tion and other genetic changes in defective measles viruses in human brain infections. Cell. 1988;55:255–265. doi: 10.1016/0092-8674(88)90048-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Cattaneo R, Kaelin K, Baczko K, Billeter MA. Measles virus editing provides an additional cysteine-rich protein. Cell. 1989a;56:759–764. doi: 10.1016/0092-8674(89)90679-x. [DOI] [PubMed] [Google Scholar]
  20. Cattaneo R, Schmid A, Spielhofer P, Kaelin K, Baczko K, ter Meulen V, Pardowitz J, Flanagan S, Rima BK, Udem SA. Mutated and hypermutated genes of persistent measles viruses which caused lethal human brain diseases. Virology. 1989b;173:415–425. doi: 10.1016/0042-6822(89)90554-0. [DOI] [PubMed] [Google Scholar]
  21. Clarke DK, Sidhu MS, Johnson JE, Udem SA. Rescue of mumps virus from cDNA. J Virol. 2000;74:4831–4838. doi: 10.1128/jvi.74.10.4831-4838.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Clarke DK, Cooper D, Egan MA, Hendry RM, Parks CL, Udem SA. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol. 2006;28:239–253. doi: 10.1007/s00281-006-0042-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Collins PL, Mink MA, Stec DS. Rescue of synthetic analogs of respiratory syncytial virus genomic RNA and effect of truncations and mutations on the expression of a foreign reporter gene. Proc Natl Acad Sci U S A. 1991;88:9663–9667. doi: 10.1073/pnas.88.21.9663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Collins PL, Mink MA, Hill MG, 3rd, Camargo E, Grosfeld H, Stec DS. Rescue of a 7502-nucleotide (49.3% of full-length) synthetic analog of respiratory syncytial virus genomic RNA. Virology. 1993;195:252–256. doi: 10.1006/viro.1993.1368. [DOI] [PubMed] [Google Scholar]
  25. Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A. 1995;92:11563–11567. doi: 10.1073/pnas.92.25.11563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Combredet C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B, McClure H, Feinberg MB, Brahic M, Tangy F. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol. 2003;77:11546–11554. doi: 10.1128/JVI.77.21.11546-11554.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Conzelmann KK, Schnell M. Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins. J Virol. 1994;68:713–719. doi: 10.1128/jvi.68.2.713-719.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Cooper D, Wright KJ, Calderon PC, Guo M, Nasar F, Johnson JE, Coleman JW, Lee M, Kotash C, Yurgelonis I, Natuk RJ, Hendry RM, Udem SA, Clarke DK. Attenuation of recom-binant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogeni-city in mice. J Virol. 2008;82:207–219. doi: 10.1128/JVI.01515-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. del Valle JR, Devaux P, Hodge G, Wegner NJ, McChesney MB, Cattaneo R. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol. 2007;81:10597–10605. doi: 10.1128/JVI.00923-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Delenda C, Taylor G, Hausmann S, Garcin D, Kolakofsky D. Sendai viruses with altered P, V, and W protein expression. Virology. 1998;242:327–337. doi: 10.1006/viro.1998.9027. [DOI] [PubMed] [Google Scholar]
  31. Despres P, Combredet C, Frenkiel MP, Lorin C, Brahic M, Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis. 2005;191:207–214. doi: 10.1086/426824. [DOI] [PubMed] [Google Scholar]
  32. Devaux P, Hodge G, McChesney MB, Cattaneo R. Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys. J Virol. 2008;82:5359–5367. doi: 10.1128/JVI.00169-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, Valdes M, Barber G, Vile RG. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 2007;67:2840–2848. doi: 10.1158/0008-5472.CAN-06-3974. [DOI] [PubMed] [Google Scholar]
  34. DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intra-nasal immunization against emerging pathogens. Proc Natl Acad Sci U S A. 2007;104:9788–9793. doi: 10.1073/pnas.0703584104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Domingo E, Sabo D, Taniguchi T, Weissmann C. Nucleotide sequence heterogeneity of an RNA phage population. Cell. 1978;13:735–744. doi: 10.1016/0092-8674(78)90223-4. [DOI] [PubMed] [Google Scholar]
  36. Duprex WP, Duffy I, McQuaid S, Hamill L, Cosby SL, Billeter MA, Schneider-Schaulies J, ter Meulen V, Rima BK. The H gene of rodent brain-adapted measles virus confers neu-rovirulence to the Edmonston vaccine strain. J Virol. 1999a;73:6916–6922. doi: 10.1128/jvi.73.8.6916-6922.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Duprex WP, McQuaid S, Hangartner L, Billeter MA, Rima BK. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol. 1999b;73:9568–9575. doi: 10.1128/jvi.73.11.9568-9575.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Duprex WP, Collins FM, Rima BK. Modulating the function of the measles virus RNA-dependent RNA polymerase by insertion of green fluorescent protein into the open reading frame. J Virol. 2002;76:7322–7328. doi: 10.1128/JVI.76.14.7322-7328.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Durbin AP, Hall SL, Siew JW, Whitehead SS, Collins PL, Murphy BR. Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology. 1997;235:323–332. doi: 10.1006/viro.1997.8697. [DOI] [PubMed] [Google Scholar]
  40. Enami M, Luytjes W, Krystal M, Palese P. Introduction of site-specific mutations into the genome of influenza virus. Proc Natl Acad Sci U S A. 1990;87:3802–3805. doi: 10.1073/pnas.87.10.3802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Erlenhofer C, Duprex WP, Rima BK, ter Meulen V, Schneider-Schaulies J. Analysis of receptor (CD46, CD150) usage by measles virus. J Gen Virol. 2002;83:1431–1436. doi: 10.1099/0022-1317-83-6-1431. [DOI] [PubMed] [Google Scholar]
  42. Escoffier C, Manie S, Vincent S, Muller CP, Billeter M, Gerlier D. Nonstructural C protein is required for efficient measles virus replication in human peripheral blood cells. J Virol. 1999;73:1695–1698. doi: 10.1128/jvi.73.2.1695-1698.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Estevez C, King D, Seal B, Yu Q. Evaluation of Newcastle disease virus chimeras expressing the Hemagglutinin-Neuraminidase protein of velogenic strains in the context of a mes-ogenic recombinant virus backbone. Virus Res. 2007;129:182–190. doi: 10.1016/j.virusres.2007.07.008. [DOI] [PubMed] [Google Scholar]
  44. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol. 1999;73:9679–9682. doi: 10.1128/jvi.73.11.9679-9682.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Garcin D, Pelet T, Calain P, Roux L, Curran J, Kolakofsky D. A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. EMBO J. 1995;14:6087–6094. doi: 10.1002/j.1460-2075.1995.tb00299.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Garcin D, Latorre P, Kolakofsky D. Sendai virus C proteins counteract the interferon-medi-ated induction of an antiviral state. J Virol. 1999;73:6559–6565. doi: 10.1128/jvi.73.8.6559-6565.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Garcin D, Curran J, Kolakofsky D. Sendai virus C proteins must interact directly with cellular components to interfere with interferon action. J Virol. 2000;74:8823–8830. doi: 10.1128/jvi.74.19.8823-8830.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Garcin D, Curran J, Itoh M, Kolakofsky D. Longer and shorter forms of Sendai virus C proteins play different roles in modulating the cellular antiviral response. J Virol. 2001;75:6800–6807. doi: 10.1128/JVI.75.15.6800-6807.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Garcin D, Marq JB, Strahle L, le Mercier P, Kolakofsky D. All four Sendai Virus C proteins bind Stat1, but only the larger forms also induce its mono-ubiquitination and degradation. Virology. 2002;295:256–265. doi: 10.1006/viro.2001.1342. [DOI] [PubMed] [Google Scholar]
  50. Ge J, Deng G, Wen Z, Tian G, Wang Y, Shi J, Wang X, Li Y, Hu S, Jiang Y, Yang C, Yu K, Bu Z, Chen H. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol. 2007;81:150–158. doi: 10.1128/JVI.01514-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Hangartner L. Development of measles virus as a vector: expression of green fluorescent protein from different loci. Master's thesis. Zurich, Switzerland: University of Zurich; 1997. [Google Scholar]
  52. He B, Paterson RG, Ward CD, Lamb RA. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology. 1997;237:249–260. doi: 10.1006/viro.1997.8801. [DOI] [PubMed] [Google Scholar]
  53. Hoffman MA, Banerjee AK. An infectious clone of human parainfluenza virus type 3. J Virol. 1997;71:4272–4277. doi: 10.1128/jvi.71.6.4272-4277.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Hoffman SJ, Polack FP, Hauer DA, Singh M, Billeter MA, Adams RJ, Griffin DE. Vaccination of rhesus macaques with a recombinant measles virus expressing interleukin-12 alters humoral and cellular immune responses. J Infect Dis. 2003;188:1553–1561. doi: 10.1086/379250. [DOI] [PubMed] [Google Scholar]
  55. Huber M, Cattaneo R, Spielhofer P, Orvell C, Norrby E, Messerli M, Perriard JC, Billeter MA. Measles virus phosphoprotein retains the nucleocapsid protein in the cytoplasm. Virology. 1991;185:299–308. doi: 10.1016/0042-6822(91)90777-9. [DOI] [PubMed] [Google Scholar]
  56. Janke M, Peeters B, de Leeuw O, Moorman R, Arnold A, Fournier P, Schirrmacher V. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther. 2007;14:1639–1649. doi: 10.1038/sj.gt.3303026. [DOI] [PubMed] [Google Scholar]
  57. Johnson JE, Nasar F, Coleman JW, Price RE, Javadian A, Draper K, Lee M, Reilly PA, Clarke DK, Hendry RM, Udem SA. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology. 2007;360:36–49. doi: 10.1016/j.virol.2006.10.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Karron R, Collins P. Parainflueza viruses. In: Knipe D, Howley P, editors. Fields virology. Wilkins, Philadelphia: Lippincott Williams; 2007. pp. 1497–1526. [Google Scholar]
  59. Kato A, Sakai Y, Shioda T, Kondo T, Nakanishi M, Nagai Y. Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells. 1996;1:569–579. doi: 10.1046/j.1365-2443.1996.d01-261.x. [DOI] [PubMed] [Google Scholar]
  60. Klenerman P, Hengartner H, Zinkernagel RM. A non-retroviral RNA virus persists in DNA form. Nature. 1997;390:298–301. doi: 10.1038/36876. [DOI] [PubMed] [Google Scholar]
  61. Kobune F, Sakata H, Sugiura A. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J Virol. 1990;64:700–705. doi: 10.1128/jvi.64.2.700-705.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Lamb R, Parks G. Paramyxoviridae: the viruses and their replication. In: Knipe D, Howley P, editors. Fields virology. Philadelphia: Lippincott Williams Wilkins; 2007. pp. 1449–1496. [Google Scholar]
  63. Lawson ND, Stillman EA, Whitt MA, Rose JK. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A. 1995;92:4477–4481. doi: 10.1073/pnas.92.10.4477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Li S, Locke E, Bruder J, Clarke D, Doolan DL, Havenga MJ, Hill AV, Liljestrom P, Monath TP, Naim HY, Ockenhouse C, Tang DC, Van Kampen KR, Viret JF, Zavala F, Dubovsky F. Viral vectors for malaria vaccine development. Vaccine. 2007;25:2567–2574. doi: 10.1016/j.vaccine.2006.07.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Liniger M, Zuniga A, Tamin A, Azzouz-Morin TN, Knuchel M, Marti RR, Wiegand M, Weibel S, Kelvin D, Rota PA, Naim HY. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine. 2008;26:2164–2174. doi: 10.1016/j.vaccine.2008.01.057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Lorence RM, Roberts MS, O'Neil JD, Groene WS, Miller JA, Mueller SN, Bamat MK. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets. 2007;7:157–167. doi: 10.2174/156800907780058853. [DOI] [PubMed] [Google Scholar]
  67. Lorin C, Mollet L, Delebecque F, Combredet C, Hurtrel B, Charneau P, Brahic M, Tangy F. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol. 2004;78:146–157. doi: 10.1128/JVI.78.1.146-157.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Luytjes W, Krystal M, Enami M, Parvin JD, Palese P. Amplification, expression, and packaging of foreign gene by influenza virus. Cell. 1989;59:1107–1113. doi: 10.1016/0092-8674(89)90766-6. [DOI] [PubMed] [Google Scholar]
  69. Lyles D, Rupprecht C. Rhabdoviridae. In: Knipe D, Howley P, editors. Fields virology. Wilkins, Philadelphia: Lippincott, Williams; 2007. pp. 1363–1408. [Google Scholar]
  70. Martin A, Staeheli P, Schneider U. RNA polymerase II-controlled expression of antige-nomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. J Virol. 2006;80:5708–5715. doi: 10.1128/JVI.02389-05. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immuno-genicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003;188:1213–1230. doi: 10.1086/378356. [DOI] [PubMed] [Google Scholar]
  72. Mrkic B, Pavlovic J, Rulicke T, Volpe P, Buchholz CJ, Hourcade D, Atkinson JP, Aguzzi A, Cattaneo R. Measles virus spread and pathogenesis in genetically modified mice. J Virol. 1998;72:7420–7427. doi: 10.1128/jvi.72.9.7420-7427.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Naim HY, Ehler E, Billeter MA. Measles virus matrix protein specifies apical virus release and glycoprotein sorting in epithelial cells. EMBO J. 2000;19:3576–3585. doi: 10.1093/emboj/19.14.3576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Nakayama T, Komase K, Uzuka R, Hoshi A, Okafuji T. Leucine at position 278 of the AIK-C measles virus vaccine strain fusion protein is responsible for reduced syncytium formation. J Gen Virol. 2001;82:2143–2150. doi: 10.1099/0022-1317-82-9-2143. [DOI] [PubMed] [Google Scholar]
  75. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E, Hobom G, Kawaoka Y. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A. 1999;96:9345–9350. doi: 10.1073/pnas.96.16.9345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Palin A, Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine. 2007;25:741–750. doi: 10.1016/j.vaccine.2006.08.010. [DOI] [PubMed] [Google Scholar]
  77. Park KH, Huang T, Correia FF, Krystal M. Rescue of a foreign gene by Sendai virus. Proc Natl Acad Sci U S A. 1991;88:5537–5541. doi: 10.1073/pnas.88.13.5537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Parks CL, Lerch RA, Walpita P, Wang HP, Sidhu MS, Udem SA. Analysis of the noncod-ing regions of measles virus strains in the Edmonston vaccine lineage. J Virol. 2001a;75:921–933. doi: 10.1128/JVI.75.2.921-933.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Parks CL, Lerch RA, Walpita P, Wang HP, Sidhu MS, Udem SA. Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage. J Virol. 2001b;75:910–920. doi: 10.1128/JVI.75.2.910-920.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Patterson JB, Cornu TI, Redwine J, Dales S, Lewicki H, Holz A, Thomas D, Billeter MA, Oldstone MB. Evidence that the hypermutated M protein of a subacute sclerosing pan-encephalitis measles virus actively contributes to the chronic progressive CNS disease. Virology. 2001;291:215–225. doi: 10.1006/viro.2001.1182. [DOI] [PubMed] [Google Scholar]
  81. Peeters BP, de Leeuw OS, Koch G, Gielkens AL. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol. 1999;73:5001–5009. doi: 10.1128/jvi.73.6.5001-5009.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Polo JM, Belli BA, Driver DA, Frolov I, Sherrill S, Hariharan MJ, Townsend K, Perri S, Mento SJ, Jolly DJ, Chang SM, Schlesinger S, Dubensky TW., Jr Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci U S A. 1999;96:4598–4603. doi: 10.1073/pnas.96.8.4598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology. 1997;239:389–401. doi: 10.1006/viro.1997.8878. [DOI] [PubMed] [Google Scholar]
  84. Racaniello VR, Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science. 1981;214:916–919. doi: 10.1126/science.6272391. [DOI] [PubMed] [Google Scholar]
  85. Radecke F, Billeter MA. The nonstructural C protein is not essential for multiplication of Edmonston B strain measles virus in cultured cells. Virology. 1996;217:418–421. doi: 10.1006/viro.1996.0134. [DOI] [PubMed] [Google Scholar]
  86. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C, Christiansen G, Billeter MA. Rescue of measles viruses from cloned DNA. EMBO J. 1995;14:5773–5784. doi: 10.1002/j.1460-2075.1995.tb00266.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Rager M, Vongpunsawad S, Duprex WP, Cattaneo R. Polyploid measles virus with hexam-eric genome length. EMBO J. 2002;21:2364–2372. doi: 10.1093/emboj/21.10.2364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Roberts A, Rose JK. Redesign and genetic dissection of the rhabdoviruses. Adv Virus Res. 1999;53:301–319. doi: 10.1016/s0065-3527(08)60353-x. [DOI] [PubMed] [Google Scholar]
  89. Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol. 1999;73:3723–3732. doi: 10.1128/jvi.73.5.3723-3732.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Rose NF, Marxn PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D, Roberts A, Buonocore L, Rose JK. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 2001;106:539–549. doi: 10.1016/s0092-8674(01)00482-2. [DOI] [PubMed] [Google Scholar]
  91. Ryan MD, Drew J. Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO J. 1994;13:928–933. doi: 10.1002/j.1460-2075.1994.tb06337.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Schmidt AC, McAuliffe JM, Huang A, Surman SR, Bailly JE, Elkins WR, Collins PL, Murphy BR, Skiadopoulos MH. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemag-glutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol. 2000;74:8922–8929. doi: 10.1128/jvi.74.19.8922-8929.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Schmidt AC, Wenzke DR, McAuliffe JM, St Claire M, Elkins WR, Murphy BR, Collins PL. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol. 2002;76:1089–1099. doi: 10.1128/JVI.76.3.1089-1099.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Schneider H, Kaelin K, Billeter MA. Recombinant measles viruses defective for RNA editing and V protein synthesis are viable in cultured cells. Virology. 1997;227:314–322. doi: 10.1006/viro.1996.8339. [DOI] [PubMed] [Google Scholar]
  95. Schnell MJ, Mebatsion T, Conzelmann KK. Infectious rabies viruses from cloned cDNA. EMBO J. 1994;13:4195–4203. doi: 10.1002/j.1460-2075.1994.tb06739.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Schnell MJ, Foley HD, Siler CA, McGettigan JP, Dietzschold B, Pomerantz RJ. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A. 2000;97:3544–3549. doi: 10.1073/pnas.050589197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Schwartz JA, Buonocore L, Roberts A, Suguitan A, Jr, Kobasa D, Kobinger G, Feldmann H, Subbarao K, Rose JK. Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology. 2007;366:166–173. doi: 10.1016/j.virol.2007.04.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Sidhu MS, Chan J, Kaelin K, Spielhofer P, Radecke F, Schneider H, Masurekar M, Dowling PC, Billeter MA, Udem SA. Rescue of synthetic measles virus minireplicons: measles genomic termini direct efficient expression and propagation of a reporter gene. Virology. 1995;208:800–807. doi: 10.1006/viro.1995.1215. [DOI] [PubMed] [Google Scholar]
  99. Simon ID, Publicover J, Rose JK. Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA. J Virol. 2007;81:2078–2082. doi: 10.1128/JVI.02525-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Singh M, Billeter MA. A recombinant measles virus expressing biologically active human interleukin-12. J Gen Virol. 1999;80:101–106. doi: 10.1099/0022-1317-80-1-101. [DOI] [PubMed] [Google Scholar]
  101. Singh M, Cattaneo R, Billeter MA. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol. 1999;73:4823–4828. doi: 10.1128/jvi.73.6.4823-4828.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Skiadopoulos MH, Surman SR, Riggs JM, Orvell C, Collins PL, Murphy BR. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology. 2002;297:136–152. doi: 10.1006/viro.2002.1415. [DOI] [PubMed] [Google Scholar]
  103. Skiadopoulos MH, Schmidt AC, Riggs JM, Surman SR, Elkins WR, St Claire M, Collins PL, Murphy BR. Determinants of the host range restriction of replication of bovine parain-fluenza virus type 3 in rhesus monkeys are polygenic. J Virol. 2003a;77:1141–1148. doi: 10.1128/JVI.77.2.1141-1148.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Skiadopoulos MH, Vogel L, Riggs JM, Surman SR, Collins PL, Murphy BR. The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations. J Virol. 2003b;77:270–279. doi: 10.1128/JVI.77.1.270-279.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Spielhofer P. Generation of standard, variant and chimeric measles viruses from cloned DNA. PhD thesis. Zurich, Switzerland: University of Zurich; 1995. [Google Scholar]
  106. Spielhofer P, Bachi T, Fehr T, Christiansen G, Cattaneo R, Kaelin K, Billeter MA, Naim HY. Chimeric measles viruses with a foreign envelope. J Virol. 1998;72:2150–2159. doi: 10.1128/jvi.72.3.2150-2159.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res. 2006;66:7694–7700. doi: 10.1158/0008-5472.CAN-06-0538. [DOI] [PubMed] [Google Scholar]
  108. Takeda M, Ohno S, Seki F, Nakatsu Y, Tahara M, Yanagi Y. Long untranslated regions of the measles virus M and F genes control virus replication and cytopathogenicity. J Virol. 2005;79:14346–14354. doi: 10.1128/JVI.79.22.14346-14354.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Takeda M, Nakatsu Y, Ohno S, Seki F, Tahara M, Hashiguchi T, Yanagi Y. Generation of measles virus with a segmented RNA genome. J Virol. 2006;80:4242–4248. doi: 10.1128/JVI.80.9.4242-4248.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Tangy F, Naim HY. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol. 2005;18:317–326. doi: 10.1089/vim.2005.18.317. [DOI] [PubMed] [Google Scholar]
  111. Tani H, Komoda Y, Matsuo E, Suzuki K, Hamamoto I, Yamashita T, Moriishi K, Fujiyama K, Kanto T, Hayashi N, Owsianka A, Patel AH, Whitt MA, Matsuura Y. Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J Virol. 2007;81:8601–8612. doi: 10.1128/JVI.00608-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Taniguchi T, Palmieri M, Weissmann C. QB DNA-containing hybrid plasmids giving rise to QB phage formation in the bacterial host. Nature. 1978;274:223–228. doi: 10.1038/274223a0. [DOI] [PubMed] [Google Scholar]
  113. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000;406:893–897. doi: 10.1038/35022579. [DOI] [PubMed] [Google Scholar]
  114. Tatsuo H, Ono N, Yanagi Y. Morbilliviruses use signaling lymphocyte activation molecules (CD150) as cellular receptors. J Virol. 2001;75:5842–5850. doi: 10.1128/JVI.75.13.5842-5850.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Tubulekas I, Berglund P, Fleeton M, Liljestrom P. Alphavirus expression vectors and their use as recombinant vaccines: a minireview. Gene. 1997;190:191–195. doi: 10.1016/s0378-1119(96)00679-8. [DOI] [PubMed] [Google Scholar]
  116. Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Johnston PB, Parker WB, Sorscher EJ, Cattaneo R. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res. 2007a;67:10939–10947. doi: 10.1158/0008-5472.CAN-07-1252. [DOI] [PubMed] [Google Scholar]
  117. Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Parker WB, Sorscher EJ, Cattaneo R. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther. 2007b;15:1991–1997. doi: 10.1038/sj.mt.6300291. [DOI] [PubMed] [Google Scholar]
  118. Valsamakis A, Schneider H, Auwaerter PG, Kaneshima H, Billeter MA, Griffin DE. Recombinant measles viruses with mutations in the C, V, or F gene have altered growth phe-notypes in vivo. J Virol. 1998;72:7754–7761. doi: 10.1128/jvi.72.10.7754-7761.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, Martinez-Sobrido L, Woo SL, Garcia-Sastre A. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 2007;67:8285–8292. doi: 10.1158/0008-5472.CAN-07-1025. [DOI] [PubMed] [Google Scholar]
  120. von Messling V, Cattaneo R. Toward novel vaccines and therapies based on negative-strand RNA viruses. Curr Topics Microbiol Immunol. 2004;283:281–312. doi: 10.1007/978-3-662-06099-5_8. [DOI] [PubMed] [Google Scholar]
  121. Wang Z, Hangartner L, Cornu TI, Martin LR, Zuniga A, Billeter MA, Naim HY. Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine. 2001;19:2329–2336. doi: 10.1016/s0264-410x(00)00523-5. [DOI] [PubMed] [Google Scholar]
  122. Wertz GW, Perepelitsa VP, Ball LA. Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci U S A. 1998;95:3501–3506. doi: 10.1073/pnas.95.7.3501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Whelan SP, Ball LA, Barr JN, Wertz GT. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A. 1995;92:8388–8392. doi: 10.1073/pnas.92.18.8388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. ZunigaN A, Wang Z, Liniger M, Hangartner L, Caballero M, Pavlovic J, Wild P, Viret JF, Glueck R, Billeter MA, Naim HY. Attenuated measles virus as a vaccine vector. Vaccine. 2007;25:2974–2983. doi: 10.1016/j.vaccine.2007.01.064. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Measles are provided here courtesy of Nature Publishing Group

RESOURCES